Bausch Health Companies, Inc. (BHC)

NYSE: BHC · IEX Real-Time Price · USD
-0.19 (-3.06%)
At close: Aug 12, 2022 4:00 PM
+0.06 (1.00%)
After-hours: Aug 12, 2022 7:55 PM EDT
Market Cap 2.17B
Revenue (ttm) 8.19B
Net Income (ttm) 43.00M
Shares Out 361.73M
EPS (ttm) 0.14
PE Ratio 42.93
Forward PE 1.38
Dividend n/a
Ex-Dividend Date n/a
Volume 6,588,147
Open 6.18
Previous Close 6.20
Day's Range 5.99 - 6.30
52-Week Range 4.00 - 29.59
Beta 1.35
Analysts Buy
Price Target 12.61 (+109.8%)
Earnings Date Aug 9, 2022

About BHC

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Sal... [Read more...]

Industry Pharmaceuticals
Employees 19,600
Stock Exchange NYSE
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2021, BHC's revenue was $8.43 billion, an increase of 5.07% compared to the previous year's $8.03 billion. Losses were -$948.00 million, 69.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for BHC stock is "Buy." The 12-month stock price forecast is 12.61, which is an increase of 109.82% from the latest price.

Price Target
(109.82% upside)
Analyst Consensus: Buy
Stock Forecasts


7 Stock Price Predictions That Are Actually Worth Listening To

Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside carefully.


Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

LAVAL, Quebec , Aug. 10, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's J...

Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down

Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.

Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)

CMS Issues New Specific ICD-10 Code K76.82 for HE LAVAL, QC , Aug. 10, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharma...

Why Bausch Health Stock Tumbled More Than 11% on Tuesday

Investors are increasingly realizing the scope of the turnaround project CEO Thomas Appio has on his plate.

Bausch Health (BHC) Q2 Earnings and Revenues Miss Estimates

Bausch (BHC) delivered earnings and revenue surprises of -38.20% and 3.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health Stock Sinks on Earnings Miss and Lowered Guidance

Bausch Health cut its revenue estimate for the year to a range between $8.05 billion and $8.22 billion, from a $8.25 billion to $8.40 billion earlier range.

Bausch's stock slides 11.8% after announcing Q2 results

Shares of Bausch Health Cos. Inc. BHC, +4.47% tumbled 11.8% in premarket trading on Tuesday after the company missed revenue expectations for the quarter, reported an unexpected loss, and lowered its re...


Revenues of $1.967 billion Company to appeal anticipated court decision and vigorously defend XIFAXAN intellectual property Balance sheet continues to improve with early retirement of $481 million of lo...

Bausch + Lomb beats earnings and revenue expectations; stock is up 3%

Shares of Bausch + Lomb Corp. BLCO, +4.15% were up 3.1% in premarket trading on Thursday after the eyecare company outperformed earnings and revenue expectations in the second quarter of 2022. Bausch ha...

Other symbols: BLCO

What's in the Cards for Bausch Health (BHC) Q2 Earnings?

An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.

Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BHC Stock Continues to Fall as Bausch Health Responds to Court Decision

Wall Street is still digesting the legal drama impacting embattled pharmaceutical firm Bausch Health (NYSE: BHC ). The company has promised to pursue all available options regarding an unfavorable decis...

Bausch Receives a Mortal Blow

Bausch Health Companies ( BHC , Financial) received a devastating body blow on Thursday when a U.S. federal court judge invalidated some key patents on its largest product Xifaxan for the treatment of i...

Bausch (BHC) Loses 39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Bausch (BHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in rev...

Bausch Health stock tumbles toward lowest close since 1995 after confirming disappointing court ruling

Shares of Bausch Health Companies Inc. BHC, -6.53% dropped 7.8% in morning trading Friday, toward a 27-year low, after the drug and medical device maker confirmed a disappointing court decision regardin...

Why Shares of Bausch Health Companies Dropped 54.4% This Week

A patent-court loss sent investors scurrying to the exits.

Bausch Health Halted After Patent Ruling. Why It Could Be the 'Worst Possible Outcome.

Bausch stock fell more than 50% Thursday before trading was halted.

Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation

-- Company to Appeal Expected Court Decision on Certain XIFAXAN® Patents – LAVAL, Quebec , July 28, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business S...

Bausch Health stock plummets toward 27-year low after Bloomberg report of unfavorable court ruling

Shares of Bausch Health Companies Inc. BHC, -50.29% suffered a near-record plunge of 50.3% in volatile afternoon trading Thursday before a trading halt, after Bloomberg reported that some of the drug an...

Bausch Health (BHC) Stock Plunges 50% on Patent News

While pharmaceutical companies often face great risks in the clinical testing arena, they can also suffer extraordinary setbacks in the courtroom, as Bausch Health (NYSE: BHC ) unfortunately demonstrate...

Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9

LAVAL, Quebec , July 27, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter financial results on Tuesday, Aug. 9, 2022. Bausch Health wil...

Investors May Want to Follow Progress of VC-Backed Medtechs

At least one group is bullish about the outlook for the medtech industry: venture capitalists.


Salix Announces 2022 Gastrointestinal Health Scholars Program Winners

For Third Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC , July 13, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bau...

Three-stock lunch: BA, WFC & BHC

Lee Munson, Portfolio Wealth Advisors president and CIO, joins ‘Power Lunch' to weigh in on three stocks: Boeing, Wells Fargo and Bausch Health.

Other symbols: BAWFC